# US 5,708,156 A · Epidermal growth factor receptor-like gene product and its uses > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 5,708,156 A - Document ID: US5708156A - Status: Granted - Kind: A - Application number: 08/658,883 - Filed: 1996-05-31 - Granted: 1998-01-13 - Earliest claimed: 1996-05-31 - Inventors: John V. Ilekis - Web page: https://patentgrep.com/patent/US5708156A ## CPC - C07K 14/71: for growth factors; for growth regulators - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract A novel human epidermal growth factor receptor-like protein has been identified, designated TEGFR. Provided herein is the nucleic acid sequence and deduced amino acid sequence of this protein. The invention relates to the measurement of its protein by immunological means or the measurement of its mRNA by recombinant DNA means in human biological samples. The invention also pertains to the use of its cDNA to produce a recombinant source of the protein. Moreover, the invention relates to its therapeutic use to inhibit the activity of epidermal growth factor receptor. Lastly, the invention also concerns the diagnostic and therapeutic use of this protein for human cancers. ## Claims ### Claim 1 An isolated nucleic acid selected from the group consisting of: nucleotides 1 through 105 and nucleotides 1713 through 1828 of SEQ ID NO:1. ### Claim 2 An isolated nucleic acid selected from the group consisting of the complement of: nucleotides 1 through 105 of SEQ ID NO:1 or fragments of at least 16 nucleotides in length thereof and nucleotides 1713 through 1828 of SEQ ID NO:1 or fragments of at least 16 nucleotides in length thereof. ### Claim 3 (depends on 2) A method of detecting the nucleic acid of SEQ ID NO:1, comprising hybridizing the isolated nucleic acid of claim 2 to the nucleic acid having the sequence of SEQ ID NO:1. ### Claim 4 An isolated polypeptide encoded by SEQ ID NO:1. ### Claim 5 (depends on 4) A composition comprising the isolated polypeptide of claim 4 and a pharmaceutically acceptable carrier. ### Claim 6 A method for the production of polyclonal or monoclonal antibodies directed against the unique carboxy terminus, SEQ ID NO:2, of the polypeptide encoded by the isolated DNA of SEQ ID NO:1 using as an antigen a peptide consisting of at least 6 amino acids and comprising the amino acid sequence of SEQ ID NO:2 used alone or conjugated to a suitable carrier as a means for eliciting an immune response, comprising the following steps: a) immunizing a host animal with said antigen in suitable vehicle, b) harvesting antibodies from said host's blood or harvesting antibodies produced by said host's antibody-producing cells or said host's antibody-producing cells fused with another cell as a means of producing antibodies outside the original said host, said antibodies directed against the unique carboxy terminus of the polypeptide encoded by the isolated DNA of SEQ ID NO:1. ### Claim 7 (depends on 6) A purified antibody produced by the method of claim 6. ### Claim 8 (depends on 6) A method of detecting a polypeptide encoded by the isolated DNA of SEQ ID NO:1 in a human biological specimen, comprising the following steps: a) contacting said specimen with the antibody produced by the method of claim 6, b) allowing said antibody a suitable time to bind, c) measuring the formation of immunoreactive complexes comprising said polypeptide and said antibody. ### Claim 9 (depends on 8) The method of claim 8 wherein said human biological specimen is selected from the group consisting of fluids, tissues and their derivatives. ### Claim 10 (depends on 8) The method according to claim 8 in which the method is used in detecting the polypeptide encoded by the isolated DNA of SEQ ID NO:1 for diagnostic purposes in human cancers. ### Claim 11 (depends on 6) A method of detecting a polypeptide encoded by the isolated DNA of SEQ ID NO:1, referred to as target polypeptide, in a human biological specimen, comprising the following steps: a) optionally separating the said target polypeptide in said specimen from interfering related polypeptides by a means based on size, charge or weight, b) contacting said specimen or said optionally separated target polypeptide with the antibody produced by the method of claim 6, c) allowing said antibody a suitable time to bind, d) measuring the formation of immunoreactive complexes. ### Claim 12 (depends on 11) The method of claim 11 wherein said human biological specimen is selected from the group consisting of fluids, tissues and their derivatives. ### Claim 13 (depends on 11) The method according to claim 11 in which the method is used in detecting the polypeptide encoded by the isolated DNA of SEQ ID NO:1 for diagnostic purposes in human cancers. ### Claim 14 A method for detecting the nucleic acid of SEQ ID NO:1, referred to as target nucleic acid, in a human biological specimen using a nucleic acid isolate selected from the group consisting of nucleotides 1 through 105 of SEQ ID NO:1 or fragments of 16 nucleotides in length thereof and nucleotides 1713 through 1828 of SEQ ID NO:1 or fragments of 16 nucleotides in length thereof, comprising the following steps: a) optionally separating the said target nucleic acid in said specimen from interfering related nucleic acids by a means based on size, charge or weight, b) adding said nucleic acid isolate to said biological specimen containing the nucleic acid encoded by SEQ ID NO:1 in the form of RNA or DNA, c) allowing said nucleic acid isolate to hybridize or anneal to said target nucleic acid, d) measuring the amount of hybridized or annealed nucleic acid complex or measuring the amount of a nucleic acid product formed that is derived from the target nucleic acid, initially present in said specimen, following amplifying said nucleic acid product. ### Claim 15 (depends on 14) The method of claim 14 wherein said human biological specimen is selected from the group consisting of fluids, tissues and their derivatives. ### Claim 16 (depends on 14) The method according to claim 14 in which the method is used in detecting the nucleic acid of SEQ ID NO:1 for diagnostic purposes in human cancers.